menu ☰
menu ˟

BLU-667 shows antitumor activity in RET-altered cancers

15 Apr 2018
Vivek SubbiahCHICAGO — BLU-667, a next-generation oncogenic RET inhibitor, demonstrated antitumor activity among patients with RET-altered tumors, according to results from an ongoing study presented at American Association for Cancer Research Annu...

Click here to view the full article which appeared in Hematology Oncology

IPH Logo